AtriCure Stock Price, News & Analysis (NASDAQ:ATRC)

$18.44 0.19 (1.04 %)
(As of 12/13/2017 07:49 AM ET)
Previous Close$18.25
Today's Range$16.18 - $18.56
52-Week Range$14.78 - $25.18
Volume239,600 shs
Average Volume197,026 shs
Market Capitalization$629.15 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Debt-to-Equity Ratio0.20%
Current Ratio2.28%
Quick Ratio1.65%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$155.11 million
Price / Sales4.10
Cash FlowN/A
Price / CashN/A
Book Value$5.07 per share
Price / Book3.64

Profitability

Trailing EPS($1.02)
Net Income$-33,330,000.00
Net Margins-19.40%
Return on Equity-20.28%
Return on Assets-12.20%

Miscellaneous

Employees500
Outstanding Shares34,470,000

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its earnings results on Wednesday, November, 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.02. The medical device company had revenue of $42.20 million for the quarter, compared to analysts' expectations of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company's quarterly revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) EPS. View AtriCure's Earnings History.

When will AtriCure make its next earnings announcement?

AtriCure is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY17 earnings guidance on Wednesday, November, 1st. The company provided EPS guidance of ($1.04)-($0.94) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.95). The company issued revenue guidance of $172-$175 million, compared to the consensus revenue estimate of $177.25 million.

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

7 brokerages have issued 1 year price targets for AtriCure's stock. Their predictions range from $24.00 to $26.00. On average, they expect AtriCure's share price to reach $24.67 in the next year. View Analyst Ratings for AtriCure.

What are Wall Street analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:

  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (10/2/2017)
  • 2. Needham & Company LLC analysts commented, "ATRC’s 2Q17 revenue, EBITDA, and EPS beat consensus and management raised its 2017 revenue guidance. Worldwide Open-Heart Ablation growth improved to 11% from 10% in 1Q17 and US Open-Heart Ablation growth improved to 14% from 12% in 1Q17. We think that the accelerating Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we think this shows that the new guidelines for ablation in concomitant open-heart procedures are driving stronger growth in this business. ATRC shares remain at a large discount to peers (2017E EV/sales of 4.4x vs. small/mid-cap growth peers at a median of 7.1x) and we reiterate our Buy rating." (7/28/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:

  • Richard M. Johnston, Independent Chairman of the Board (Age 82)
  • Michael H. Carrel, President, Chief Executive Officer, Director (Age 46)
  • M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President (Age 42)
  • Douglas J. Seith, Chief Operating Officer (Age 51)
  • Justin J. Noznesky, Senior Vice President, Marketing and Business Development (Age 39)
  • Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality (Age 65)
  • Salvatore Privitera, Chief Technology Officer (Age 44)
  • Mark A. Collar, Independent Director (Age 64)
  • Scott William Drake, Independent Director (Age 49)
  • Regina E. Groves, Independent Director (Age 58)

Who owns AtriCure stock?

AtriCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (3.00%), Peregrine Capital Management LLC (2.69%), Neuberger Berman Group LLC (2.61%), Emerald Advisers Inc. PA (1.63%), Emerald Mutual Fund Advisers Trust (1.45%) and Cortina Asset Management LLC (1.28%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell and M Andrew Wade. View Institutional Ownership Trends for AtriCure.

Who sold AtriCure stock? Who is selling AtriCure stock?

AtriCure's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Axiom International Investors LLC DE, Perkins Capital Management Inc., Royce & Associates LP, Keybank National Association OH, Wasatch Advisors Inc. and California State Teachers Retirement System. Company insiders that have sold AtriCure company stock in the last year include Andrew L Lux, Elizabeth D Krell and M Andrew Wade. View Insider Buying and Selling for AtriCure.

Who bought AtriCure stock? Who is buying AtriCure stock?

AtriCure's stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Cortina Asset Management LLC, Neuberger Berman Group LLC, Quantum Capital Management, JPMorgan Chase & Co., Peregrine Capital Management LLC, Allianz Asset Management GmbH and Nationwide Fund Advisors. View Insider Buying and Selling for AtriCure.

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of AtriCure stock can currently be purchased for approximately $18.44.

How big of a company is AtriCure?

AtriCure has a market capitalization of $629.15 million and generates $155.11 million in revenue each year. The medical device company earns $-33,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. AtriCure employs 500 workers across the globe.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (ATRC)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AtriCure (NASDAQ:ATRC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.882.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.75$24.00$23.88$23.25
Price Target Upside: 32.24% upside11.94% upside0.15% upside6.07% upside

AtriCure (NASDAQ:ATRC) Consensus Price Target History

Price Target History for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2017Piper Jaffray CompaniesReiterated RatingBuy$24.00LowView Rating Details
11/2/2017Canaccord GenuityLower Price TargetBuy$28.00 -> $24.00N/AView Rating Details
11/2/2017Needham & Company LLCLower Price TargetBuy -> Buy$26.00 -> $25.00N/AView Rating Details
7/30/2017Stifel NicolausReiterated RatingBuy$25.00MediumView Rating Details
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

AtriCure (NASDAQ:ATRC) Earnings History and Estimates Chart

Earnings by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ ATRC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.21)N/AView Earnings Details
11/1/2017Q3 2017($0.24)($0.22)$43.44 million$42.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.26)($0.21)$44.15 million$45.23 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.32)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

AtriCure (NASDAQ:ATRC) Earnings Estimates

2017 EPS Consensus Estimate: ($1.06)
2018 EPS Consensus Estimate: ($0.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.17)($0.17)($0.17)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.14)($0.14)($0.14)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AtriCure (NASDAQ:ATRC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AtriCure (NASDAQ ATRC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.90%
Institutional Ownership Percentage: 86.17%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ ATRC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017M. Andrew WadeCFOSell2,000$18.41$36,820.00View SEC Filing  
11/8/2017B Kristine JohnsonDirectorBuy1,500$18.36$27,540.00View SEC Filing  
8/22/2017Elizabeth D KrellDirectorSell10,000$22.40$224,000.00View SEC Filing  
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.00View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.00View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AtriCure (NASDAQ ATRC) News Headlines

Source:
DateHeadline
ETFs with exposure to AtriCure, Inc. : December 11, 2017ETFs with exposure to AtriCure, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:23 PM
AtriCures (ATRC) "Buy" Rating Reaffirmed at Piper Jaffray CompaniesAtriCure's (ATRC) "Buy" Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - December 11 at 1:26 PM
AtriCure, Inc. (ATRC) Expected to Post Quarterly Sales of $45.27 MillionAtriCure, Inc. (ATRC) Expected to Post Quarterly Sales of $45.27 Million
www.americanbankingnews.com - December 6 at 9:50 AM
-$0.21 Earnings Per Share Expected for AtriCure, Inc. (ATRC) This Quarter-$0.21 Earnings Per Share Expected for AtriCure, Inc. (ATRC) This Quarter
www.americanbankingnews.com - December 4 at 9:18 AM
M. Andrew Wade Sells 2,000 Shares of AtriCure, Inc. (ATRC) StockM. Andrew Wade Sells 2,000 Shares of AtriCure, Inc. (ATRC) Stock
www.americanbankingnews.com - December 1 at 10:50 PM
ETFs with exposure to AtriCure, Inc. : December 1, 2017ETFs with exposure to AtriCure, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 3:25 PM
AtriCure, Inc. (ATRC) Receives Average Rating of "Hold" from AnalystsAtriCure, Inc. (ATRC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 2:00 PM
AtriCure, Inc. (ATRC) Rating Lowered to Sell at ValuEngineAtriCure, Inc. (ATRC) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - November 25 at 8:10 AM
ETFs with exposure to AtriCure, Inc. : November 20, 2017ETFs with exposure to AtriCure, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 5:28 PM
$45.27 Million in Sales Expected for AtriCure, Inc. (ATRC) This Quarter$45.27 Million in Sales Expected for AtriCure, Inc. (ATRC) This Quarter
www.americanbankingnews.com - November 17 at 3:58 AM
AtriCure to Present at the Piper Jaffray 29th Annual Healthcare ConferenceAtriCure to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 9 at 5:22 PM
Insider Buying: AtriCure, Inc. (ATRC) Director Acquires 1,500 Shares of StockInsider Buying: AtriCure, Inc. (ATRC) Director Acquires 1,500 Shares of Stock
www.americanbankingnews.com - November 9 at 3:28 PM
ETFs with exposure to AtriCure, Inc. : November 8, 2017ETFs with exposure to AtriCure, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 6:29 PM
AtriCure, Inc. :ATRC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017AtriCure, Inc. :ATRC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 5:58 PM
FY2017 Earnings Estimate for AtriCure, Inc. (ATRC) Issued By Leerink SwannFY2017 Earnings Estimate for AtriCure, Inc. (ATRC) Issued By Leerink Swann
www.americanbankingnews.com - November 6 at 8:00 AM
AtriCure Becomes Oversold (ATRC)AtriCure Becomes Oversold (ATRC)
www.thestreet.com - November 3 at 9:09 AM
Edited Transcript of ATRC earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of ATRC earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 4:42 PM
AtriCure, Inc. (ATRC) Announces  Earnings ResultsAtriCure, Inc. (ATRC) Announces Earnings Results
www.americanbankingnews.com - November 2 at 2:36 PM
AtriCure, Inc. (ATRC) Receives Consensus Rating of "Buy" from AnalystsAtriCure, Inc. (ATRC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 12:02 PM
AtriCure, Inc. (ATRC) Releases FY17 Earnings GuidanceAtriCure, Inc. (ATRC) Releases FY17 Earnings Guidance
www.americanbankingnews.com - November 1 at 5:26 PM
AtriCure Reports Third Quarter 2017 Financial ResultsAtriCure Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 4:48 PM
Zacks: Analysts Expect AtriCure, Inc. (ATRC) Will Post Quarterly Sales of $43.90 MillionZacks: Analysts Expect AtriCure, Inc. (ATRC) Will Post Quarterly Sales of $43.90 Million
www.americanbankingnews.com - October 28 at 10:42 AM
Head-To-Head Survey: AtriCure (ATRC) and The CompetitionHead-To-Head Survey: AtriCure (ATRC) and The Competition
www.americanbankingnews.com - October 28 at 8:22 AM
AtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : October 26, 2017AtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : October 26, 2017
finance.yahoo.com - October 26 at 4:11 PM
 Analysts Expect AtriCure, Inc. (ATRC) to Announce -$0.24 EPS Analysts Expect AtriCure, Inc. (ATRC) to Announce -$0.24 EPS
www.americanbankingnews.com - October 26 at 11:36 AM
AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : October 25, 2017AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : October 25, 2017
finance.yahoo.com - October 25 at 5:20 PM
AtriCure to Present at the Stifel Healthcare ConferenceAtriCure to Present at the Stifel Healthcare Conference
finance.yahoo.com - October 20 at 5:58 PM
AtriCure to Present at the Stifel Healthcare ConferenceAtriCure to Present at the Stifel Healthcare Conference
finance.yahoo.com - October 20 at 5:58 PM
AtriCure Inc. (ATRC) Set to Announce Quarterly Earnings on WednesdayAtriCure Inc. (ATRC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 2:58 AM
Mike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of DirectorsMike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of Directors
finance.yahoo.com - October 11 at 5:39 PM
AtriCure to Announce Third Quarter 2017 Financial ResultsAtriCure to Announce Third Quarter 2017 Financial Results
finance.yahoo.com - October 10 at 5:28 PM
AtriCure, Inc. (ATRC) Rating Reiterated by Canaccord GenuityAtriCure, Inc. (ATRC) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - October 9 at 6:55 AM
AtriCure, Inc. (ATRC) Receives Consensus Rating of "Buy" from BrokeragesAtriCure, Inc. (ATRC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 8 at 11:02 AM
 Analysts Anticipate AtriCure, Inc. (ATRC) Will Post Earnings of -$0.24 Per Share Analysts Anticipate AtriCure, Inc. (ATRC) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - October 7 at 12:12 PM
Head to Head Review: AtriCure (ATRC) versus Its PeersHead to Head Review: AtriCure (ATRC) versus Its Peers
www.americanbankingnews.com - October 2 at 10:06 PM
AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : September 28, 2017AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : September 28, 2017
finance.yahoo.com - October 2 at 4:04 PM
Financial Analysis: CryoLife (CRY) and AtriCure (ATRC)Financial Analysis: CryoLife (CRY) and AtriCure (ATRC)
www.americanbankingnews.com - September 26 at 4:28 AM
AtriCure, Inc. (ATRC) Receives Consensus Recommendation of "Buy" from AnalystsAtriCure, Inc. (ATRC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 10:50 AM
AtriCure, Inc. (ATRC) Presents at Morgan Stanley 2017 Global Healthcare Conference (Transcript)AtriCure, Inc. (ATRC) Presents at Morgan Stanley 2017 Global Healthcare Conference (Transcript)
seekingalpha.com - September 13 at 2:29 AM
AtriCure Announces U.S. Launch of the AtriClip® PRO•V™ DeviceAtriCure Announces U.S. Launch of the AtriClip® PRO•V™ Device
finance.yahoo.com - September 12 at 4:24 PM
AtriCure (ATRC) & DENTSPLY SIRONA (XRAY) Head to Head SurveyAtriCure (ATRC) & DENTSPLY SIRONA (XRAY) Head to Head Survey
www.americanbankingnews.com - September 9 at 12:20 PM
AtriCure, Inc. (ATRC) Expected to Post Earnings of -$0.24 Per ShareAtriCure, Inc. (ATRC) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - August 31 at 8:08 AM
Head-To-Head Comparison: Landauer (LDR) versus AtriCure (ATRC)Head-To-Head Comparison: Landauer (LDR) versus AtriCure (ATRC)
www.americanbankingnews.com - August 30 at 4:08 AM
AtriCure, Inc. (ATRC) Director Sells $224,000.00 in StockAtriCure, Inc. (ATRC) Director Sells $224,000.00 in Stock
www.americanbankingnews.com - August 23 at 1:14 PM
AtriCure, Inc. (ATRC) Receives Average Recommendation of "Buy" from AnalystsAtriCure, Inc. (ATRC) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 11:20 AM
AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2017AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2017
finance.yahoo.com - August 15 at 5:06 PM
ETFs with exposure to AtriCure, Inc. : August 15, 2017ETFs with exposure to AtriCure, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 5:06 PM
Intersect ENT (XENT) versus AtriCure (ATRC) Head to Head ReviewIntersect ENT (XENT) versus AtriCure (ATRC) Head to Head Review
www.americanbankingnews.com - August 13 at 6:08 AM
-$0.24 Earnings Per Share Expected for AtriCure, Inc. (NASDAQ:ATRC) This Quarter-$0.24 Earnings Per Share Expected for AtriCure, Inc. (NASDAQ:ATRC) This Quarter
www.americanbankingnews.com - August 12 at 8:10 PM
AtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017AtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 1 at 5:05 PM

SEC Filings

AtriCure (NASDAQ:ATRC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AtriCure (NASDAQ:ATRC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AtriCure (NASDAQ ATRC) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.